Cinical Trials

with ChAd3 Ebola Zaire, Ebola Sudan and/or Marburg

Under an agreement with GSK, Sabin has exclusively licensed the technology for clinical-stage vaccine candidates against Ebola Sudan, Ebola Zaire and Marburg viruses. The three vaccine candidates have demonstrated strong safety profiles across 13 different clinical trials, beginning in 2014. The table below outlines the completed and ongoing clinical trials using ChAd3 Ebola Zaire, Ebola Sudan and/or Marburg. For more information and to view the full protocols, click on the links to clinicaltrials.gov.

Studies conducted from 2014-Present (2 ongoing trials)

   Study 

Virus

Vaccine(s)

Sponsor

Subjects 

A study to examine safety, tolerability and immunogenicity of an investigational Marburg vaccine given by intramuscular (IM) injection to healthy adults NCT03475056

Phase 1, Ongoing

Marburg RV507

cAd3-MarburgNIAID (USA)40

A dose-escalation clinical trial to evaluate the safety, tolerability and immunogenicity of an Ebola Sudan chimpanzee adenovirus vector vaccine in healthy adults 

Phase 1, Ongoing

Sudan RV508

 cAd3-EBO-SNIAID (Uganda)40 (Target)

A dose-escalating, safety and immunogenicity trial of the monovalent Zaire Ebola viral vector candidate vaccine cAd3-EBO Z and the heterologous prime-boost candidate vaccine regimen cAd3-EBO Z and MVA-BN® Filo in healthy UK Adults NCT02240875

Phase 1 ​(Data used for dose selection for Phase 2/3)

Zaire, Ebola Sudan, Marburg

cAd3-EBO Z

MVA-BN® Filo

Univ of Oxford (UK)91

A clinical trial to assess the safety and immunogenicity of MVA-EBO Z alone and a heterologous prime-boost immunization with ChAd3-EBO Z and MVA-EBO Z in healthy UK volunteers NCT02451891

Phase 1 ​(Data used for dose selection for Phase 2/3)

Zaire

MVA-EBO Z

ChAd3-EBO Z

Univ of Oxford (UK)38

A safety and immunogenicity trial of the heterologous prime-boost regimen combining the monovalent Zaire Ebola viral vector candidates ChAd3-EBO-Z and Ad26.ZEBOV in healthy UK adults NCT02495246

Phase 1 ​(Data used for dose selection for Phase 2/3)
Zaire 

ChAd3-EBO-Z

Ad26.ZEBOV

Univ of Oxford (UK)32

A dose-escalation clinical trial to evaluate the safety, tolerability and immunogenicity of Ebola chimpanzee adenovirus vector vaccines in healthy adults NCT02231866

Phase 1/1b

Zaire, Sudan

VRC 207

cAd3-EBO

cAd3-EBOZ 

NIAID (USA)143

An open-label clinical trial to evaluate dose, safety and immunogenicity of recombinant modified vaccinia virus Ankara Ebola vaccine administered alone or as boost to cAd3-Ebola vaccines in healthy adults NCT02408913

Phase 1/1b

Zaire

VRC 208

MVA-EbolaZ

cAd3-EBO

NIAID (USA)140

An open-label clinical trial to evaluate safety, tolerability and immunogenicity of the investigational Ebola vaccines, VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP and VRC-EBOMVA079-00-VP in healthy adults in Kampala Uganda NCT02354404

Phase 1b

Zaire, Sudan

RV422 part 1 and part 2

cAd3-EBOZ

cAd3-EBO

MVA-EbolaZ

NIAID (Uganda)90; 66/90

A double-blind clinical trial to evaluate the safety, tolerability and immunogenicity of two different dosage levels of Ebola chimpanzee adenovirus vector vaccine (cAd3-EBO) and the heterologous prime-boost candidate vaccine regimen of cAd3-EBO followed by MVA-vectored vaccine in healthy adults in Bamako, Mali NCT02368119

Phase 1b

Zaire, Sudan

CVD02

cAd3-EBO

MVA-EbolaZ

Univ of Maryland (Mali)60

A dose-escalating safety and immunogenicity trial of the novel monovalent Ebola Zaire candidate vaccine, cAd3-EBO Z and the heterologous prime-boost candidate vaccine regimen of cAd3-EBO Z followed by MVA-BN® Filo in Malian adults NCT02267109

Phase 1b

Zaire

CVD01

cAd3-EBO Z

Booster-MVA-BN® Filo 

Univ of Maryland (Mali)91

A safety and immunogenicity clinical trial of heterologous prime-boost immunization with ChAd3-EBO Z and MVA-EBO Z in healthy Senegalese adult volunteers NCT02485912

Phase 1b ​(Data used for dose selection for Phase 2/3)

Zaire

ChAd3-EBO Z

MVA-EBO Z

Univ of Oxford (Senegal)40

A double-blind, randomized, placebo controlled, safety and immunogenicity, dose-finding trial of the monovalent Zaire Ebola chimpanzee adenovirus vector candidate vaccine cAd3-EBOZ in healthy adults in Switzerland NCT02289027

Phase 1/2 (Data used for dose selection for Phase 2/3)
 

Zaire

CHUV

cAd3-EBOZ

Centre Hospitalier Universitaire Vaudois (Switzerland)

120

A study to evaluate the safety and immunogenicity of an investigational recombinant chimpanzee adenovirus type 3-vectored Ebola Zaire vaccine in adults in Africa NCT02485301

Phase 2

ZaireChAd3-EBO-ZGSK (Cameroon, Nigeria, Senegal, Mali)3024

A study to evaluate the safety and immunogenicity of an investigational recombinant chimpanzee adenovirus type 3-vectored Ebola Zaire vaccine in children in Africa NCT02548078

Phase 2

ZaireChAd3-EBO-ZGSK (Senegal, Mali)600

Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) NCT02344407

Phase 2

Zaire

VSVG-ZEBOV

ChAd3-EBO Z

NIAID (Liberia)1500

Clinical Trials by Phase